Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-design,
exploratory study of orally administered ERB-041 in subjects with active IC. The primary
objectives of this study will be to investigate ERB-041's activity on levels of urinary APF,
explore the gene expression response in peripheral blood mononuclear cells (PBMC), and to
evaluate the safety of ERB-041 in women with active IC.